WO2010134939A3 - Mammalian genes involved in infection - Google Patents

Mammalian genes involved in infection Download PDF

Info

Publication number
WO2010134939A3
WO2010134939A3 PCT/US2009/069036 US2009069036W WO2010134939A3 WO 2010134939 A3 WO2010134939 A3 WO 2010134939A3 US 2009069036 W US2009069036 W US 2009069036W WO 2010134939 A3 WO2010134939 A3 WO 2010134939A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
genes involved
mammalian genes
involved
sequences
Prior art date
Application number
PCT/US2009/069036
Other languages
French (fr)
Other versions
WO2010134939A2 (en
Inventor
Donald Rubin
Thomas Hodge
James Murray
Natalie Mcdonald
Original Assignee
Zirus, Inc.
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zirus, Inc., Vanderbilt University filed Critical Zirus, Inc.
Publication of WO2010134939A2 publication Critical patent/WO2010134939A2/en
Publication of WO2010134939A3 publication Critical patent/WO2010134939A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to nucleic acid sequences and cellular proteins encoded by these sequences that are involved in infection or are otherwise associated with the life cycle of one or more pathogens.
PCT/US2009/069036 2008-12-19 2009-12-21 Mammalian genes involved in infection WO2010134939A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20321308P 2008-12-19 2008-12-19
US61/203,213 2008-12-19

Publications (2)

Publication Number Publication Date
WO2010134939A2 WO2010134939A2 (en) 2010-11-25
WO2010134939A3 true WO2010134939A3 (en) 2011-03-31

Family

ID=43126678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/069036 WO2010134939A2 (en) 2008-12-19 2009-12-21 Mammalian genes involved in infection

Country Status (1)

Country Link
WO (1) WO2010134939A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
ES2710109T3 (en) * 2010-12-17 2019-04-23 Inst Nat Sante Rech Med Nucleic acids that target TCTP for use in the treatment of chemoresistant or hormone-resistant cancers
CN103215345B (en) * 2012-01-20 2018-04-06 中国农业科学院上海兽医研究所 Suppress host's related gene and its screening technique and the application that influenza virus is replicated
CN105602989B (en) * 2012-01-20 2019-04-02 中国农业科学院上海兽医研究所 A kind of recombinant vector and its application in preparation or screening Tamiflu
WO2014022185A2 (en) * 2012-08-03 2014-02-06 Albert Einstein College Of Medicine Of Yeshiva University Method to treat or prevent herpesvirus infections
WO2016047595A1 (en) * 2014-09-22 2016-03-31 国立研究開発法人科学技術振興機構 Cell for producing influenza virus, and method for producing influenza virus
KR102496025B1 (en) * 2014-09-22 2023-02-03 고쿠리츠켄큐카이하츠호진 카가쿠기쥬츠신코키코 Anti-influenza virus agent, and screening method for anti-influenza virus agent
JP6967810B2 (en) * 2017-07-28 2021-11-17 レモネックス インコーポレイテッドLemonex Inc. Pharmaceutical composition for the prevention or treatment of liver cancer
JP7364664B2 (en) 2019-03-26 2023-10-18 富士フイルム株式会社 Pharmaceutical composition inhibiting production of hepatitis B virus protein, pharmaceutical composition and screening method for treating hepatitis B
WO2021016293A1 (en) * 2019-07-22 2021-01-28 University Of Louisville Research Foundation, Inc. Immunomodulatory compositions and methods of using
WO2021102435A1 (en) * 2019-11-22 2021-05-27 Research Institute At Nationwide Children's Hospital Materials and methods for treatment of disorders associated with the ighmbp2 gene
CN111214663B (en) * 2020-03-06 2022-03-15 中国人民解放军军事科学院军事医学研究院 Application of TMED2 as target point for treating Ebola virus disease
CN116249538A (en) 2020-09-30 2023-06-09 富士胶片株式会社 Double-stranded RNA for inhibiting production of hepatitis B virus protein and pharmaceutical composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049113A1 (en) * 2000-05-30 2001-12-06 Lee Patrick W.K. Diagnosis and treatment of herpes infections
US20020037888A1 (en) * 1998-12-08 2002-03-28 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20050085529A1 (en) * 2003-10-21 2005-04-21 Board Of Regents The University Of Texas System Prenylation inhibitors reduce host cell permissiveness to viral replication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037888A1 (en) * 1998-12-08 2002-03-28 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20010049113A1 (en) * 2000-05-30 2001-12-06 Lee Patrick W.K. Diagnosis and treatment of herpes infections
US20050085529A1 (en) * 2003-10-21 2005-04-21 Board Of Regents The University Of Texas System Prenylation inhibitors reduce host cell permissiveness to viral replication

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KELLY, ROSEMARIE ET AL.: "Geranylgeranyltransferase I of Candida albicans: N ull Mutants or Enzyme Inhitiors Produce Unexpected Phenotypes", JOURNAL OF B ACTERIOLOGY, vol. 182, no. 3, 2000, pages 704 - 713 *
KIM, KI-WOO ET AL.: "Inactivation of farnesyltransferase and geranylgeranylt ransferase I by caspase-3: Cleavage of the common a subunit during apoptosi s", ONCOGENE, vol. 20, 2001, pages 358 - 366 *
PRENDERGAST, GEORGE C ET AL.: "Negative Growth Selection agaist Rodent Fibro blasts Targeted for genetic inhibition of Farnesyl Transferase", CELL GROWTH & DIFFERENTIATION, vol. 4, 1993, pages 707 - 713 *
ROLLAND, DELPHINE ET AL.: "Farnesyltransferase inhibitor R115777 inhibits ce 11 growth and induces apoptosis in mantle cell lymphoma", CANCER. CHEMOTHER. PHARCOL., vol. 61, no. 5, April 2008 (2008-04-01), pages 855 - 863, XP019587388 *

Also Published As

Publication number Publication date
WO2010134939A2 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
WO2011008956A3 (en) Mammalian genes involved in infection
WO2010134939A3 (en) Mammalian genes involved in infection
WO2010039778A3 (en) Mammalian genes involved in infection
WO2006047673A3 (en) Mammalian genes involved in infection
WO2011146527A3 (en) Mammalian genes involved in infection
WO2010110914A3 (en) Mammalian genes involved in infection
WO2011063308A3 (en) Beta-glucosidase variants with improved properties
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
EP2274442A4 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
GB2470672B (en) Methods of RNA amplification in the presence of DNA
PE20190843A1 (en) RNA ADDRESSING TO GENERIC DNA
WO2009120374A3 (en) Methods and compositions for nucleic acid sample preparation
WO2010127304A3 (en) Sequencing methods
WO2009126623A3 (en) Expression of heterologous sequences
MX2013012844A (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same.
ZA201008749B (en) Isothermal nucleic acid amplification
EP2508613A3 (en) Glycosylation of molecules
EP2377928A3 (en) Novel T7 RNA polymerase variants with enhanced thermostability
HK1142928A1 (en) Nucleic acid amplification in the presence of modified randomers
WO2007084488A3 (en) Adam10 and its uses related to infection
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
WO2012045067A3 (en) Mammalian genes involved in infection
WO2010144908A3 (en) Mammalian genes involved in tularemia and other infections
IN2012DN00172A (en)
WO2010058393A3 (en) Compositions and methods for the prognosis of colon cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09845048

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09845048

Country of ref document: EP

Kind code of ref document: A2